JAI RESEARCH FOUNDATION

JAI RESEARCH FOUNDATION specializes in preclinical pharmaceutical development services, with a focused expertise in solubility, stability, and toxicology studies essential for advancing novel drug candidates from discovery into clinical trials. The organization provides critical pharmacological data required by regulatory bodies to assess the viability and safety of investigational therapeutics, leveraging laboratory-based analytical methods to characterize drug behavior under physiological conditions. Their technical capabilities include in vitro and in vivo assessment protocols, pharmacokinetic profiling, and formulation stability testing—all aligned with FDA and ICH guidelines to support IND-enabling packages. This narrow but high-impact specialization positions them as a precision-focused partner for early-stage drug development programs requiring rigorous, reproducible data generation. The contractor has demonstrated direct engagement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the Department of Health and Human Services, supporting NIH-led drug discovery initiatives. Their work centers on generating the nonclinical safety and physicochemical data necessary to transition proprietary compounds from laboratory research into human testing, indicating a trusted, mission-aligned relationship with federal biomedical research entities. Their primary industry focus is within testing laboratories and services (NAICS 541380), serving the biopharmaceutical research sector with specialized preclinical support. They operate at the intersection of pharmaceutical science and regulatory compliance, targeting niche markets where robust, scalable data generation is a bottleneck in drug development pipelines. JAI RESEARCH FOUNDATION maintains a lean operational structure with no public certifications on record. Their geographic presence and organizational scale are not disclosed, but their contract activity suggests a focused, mission-driven entity serving federal biomedical research priorities without broad commercial or defense market exposure.